Last reviewed · How we verify
Fluad Vaccine
Fluad Vaccine is a Inactivated influenza vaccine with adjuvant Small molecule drug developed by David H. Canaday. It is currently FDA-approved for Seasonal influenza prevention in adults aged 18 years and older. Also known as: adjuvanted influenza vaccine.
Fluad is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.
The Fluad Vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is used to study and potentially prevent influenza in older adults, as part of a broader research effort to analyze next-generation influenza vaccines in this demographic.
At a glance
| Generic name | Fluad Vaccine |
|---|---|
| Also known as | adjuvanted influenza vaccine |
| Sponsor | David H. Canaday |
| Drug class | Inactivated influenza vaccine with adjuvant |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fluad contains inactivated influenza virus antigens that trigger both humoral and cellular immune responses, enabling the body to recognize and neutralize circulating influenza viruses. The vaccine is formulated with an adjuvant (MF59) to enhance immunogenicity, particularly in older adults and immunocompromised populations. This approach provides protection against seasonal influenza infection and reduces severity of disease if breakthrough infection occurs.
Approved indications
- Seasonal influenza prevention in adults aged 18 years and older
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
- Open-Label Influenza Vaccine Evaluation (NA)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults (PHASE4)
- Systems Investigation of Vaccine Responses in Aging and Frailty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluad Vaccine CI brief — competitive landscape report
- Fluad Vaccine updates RSS · CI watch RSS
- David H. Canaday portfolio CI
Frequently asked questions about Fluad Vaccine
What is Fluad Vaccine?
How does Fluad Vaccine work?
What is Fluad Vaccine used for?
Who makes Fluad Vaccine?
Is Fluad Vaccine also known as anything else?
What drug class is Fluad Vaccine in?
What development phase is Fluad Vaccine in?
What are the side effects of Fluad Vaccine?
Related
- Drug class: All Inactivated influenza vaccine with adjuvant drugs
- Manufacturer: David H. Canaday — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults aged 18 years and older
- Also known as: adjuvanted influenza vaccine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing